About REMICADE (infliximab)

REMICADE® (infliximab) has over 20 years of experience of treating patients with immune-mediated diseases in the field of Rheumatology, Gastroenterology and Dermatology1


REMICADE is a monoclonal antibody; it is a TNFα (Tumour Necrosis Factor– alpha) inhibitor that is indicated for the treatment of a range of immune-mediated inflammatory disorders.1

REMICADE is a prescription-only product. It is presented as powder (100 mg/vial) to be reconstituted with water, diluted with saline and thereafter administered via intravenous infusion.1

IE-GOL-00063|Date of preparation: November 2020